ArticleFrontiers in medicine2026
Airway pressure release ventilation in acute severe asthma: a case series and physiologic framework.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute severe asthma causes airflow obstruction, dynamic hyperinflation, and progressive hypercapnic respiratory failure. Conventional ventilation prioritizes prolonged expiratory times and permissive hypercapnia to limit air trapping, but some patients develop refractory hypercapnia requiring consideration of extracorporeal support. Airway pressure release ventilation (APRV) is traditionally used in hypoxemic respiratory failure, and its role in obstructive lung disease remains poorly defined. Methods: We conducted a retrospective case series of adult patients with acute severe asthma who required invasive mechanical ventilation and underwent extracorporeal membrane oxygenation (ECMO) consultation at a tertiary academic center. Clinical characteristics, ventilatory parameters, arterial blood gases, and outcomes were collected. The primary outcome was change in PaCO Results: Six patients with marked hypercapnic respiratory failure (pre-APRV PaCO Conclusion: Following transition to APRV, hypercapnia and acidemia improved and none of the five rescue patients proceeded to ECMO cannulation. Whether this reflects APRV, concurrent medical therapy, or the natural course of treated bronchospasm cannot be determined from this small uncontrolled series. These observations suggest a flow-guided airway pressure release ventilation-time-controlled adaptive ventilation (APRV-TCAV) protocol was feasible and was applied without new barotrauma in refractory obstructive respiratory failure. Prospective controlled evaluation is needed to define APRV's role and identify patient phenotypes most likely to benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.